Free Trial

STERIS (STE) Competitors

STERIS logo
$220.43 -0.36 (-0.16%)
Closing price 03:59 PM Eastern
Extended Trading
$220.54 +0.10 (+0.05%)
As of 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STE vs. BDX, EW, IDXX, DXCM, RMD, PODD, BAX, HOLX, GMED, and MASI

Should you be buying STERIS stock or one of its competitors? The main competitors of STERIS include Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), Insulet (PODD), Baxter International (BAX), Hologic (HOLX), Globus Medical (GMED), and Masimo (MASI). These companies are all part of the "health care equipment" industry.

STERIS vs.

STERIS (NYSE:STE) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation, dividends and community ranking.

STERIS has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.

STERIS pays an annual dividend of $2.28 per share and has a dividend yield of 1.0%. Becton, Dickinson and Company pays an annual dividend of $4.16 per share and has a dividend yield of 1.8%. STERIS pays out 48.4% of its earnings in the form of a dividend. Becton, Dickinson and Company pays out 69.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. STERIS has increased its dividend for 20 consecutive years and Becton, Dickinson and Company has increased its dividend for 53 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

STERIS has a net margin of 8.66% compared to Becton, Dickinson and Company's net margin of 8.47%. Becton, Dickinson and Company's return on equity of 15.74% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
STERIS8.66% 13.91% 8.64%
Becton, Dickinson and Company 8.47%15.74%7.29%

In the previous week, Becton, Dickinson and Company had 34 more articles in the media than STERIS. MarketBeat recorded 48 mentions for Becton, Dickinson and Company and 14 mentions for STERIS. Becton, Dickinson and Company's average media sentiment score of 1.51 beat STERIS's score of 1.40 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
STERIS
11 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Becton, Dickinson and Company
42 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Becton, Dickinson and Company has higher revenue and earnings than STERIS. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STERIS$5.14B4.21$378.24M$4.7146.80
Becton, Dickinson and Company$20.18B3.24$1.71B$6.0237.80

Becton, Dickinson and Company received 262 more outperform votes than STERIS when rated by MarketBeat users. Likewise, 62.43% of users gave Becton, Dickinson and Company an outperform vote while only 59.19% of users gave STERIS an outperform vote.

CompanyUnderperformOutperform
STERISOutperform Votes
338
59.19%
Underperform Votes
233
40.81%
Becton, Dickinson and CompanyOutperform Votes
600
62.43%
Underperform Votes
361
37.57%

94.7% of STERIS shares are held by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are held by institutional investors. 1.1% of STERIS shares are held by company insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

STERIS presently has a consensus price target of $258.75, indicating a potential upside of 17.38%. Becton, Dickinson and Company has a consensus price target of $278.29, indicating a potential upside of 22.30%. Given Becton, Dickinson and Company's stronger consensus rating and higher possible upside, analysts clearly believe Becton, Dickinson and Company is more favorable than STERIS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STERIS
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Becton, Dickinson and Company
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Becton, Dickinson and Company beats STERIS on 13 of the 21 factors compared between the two stocks.

Get STERIS News Delivered to You Automatically

Sign up to receive the latest news and ratings for STE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STE vs. The Competition

MetricSTERISSurgical appliances & supplies IndustryMedical SectorNYSE Exchange
Market Cap$21.66B$10.18B$5.80B$20.04B
Dividend Yield1.03%1.38%4.78%3.65%
P/E Ratio46.8018.2426.4134.90
Price / Sales4.2142.45450.1415.61
Price / Cash15.7719.4144.0420.85
Price / Book3.375.407.634.92
Net Income$378.24M$284.66M$3.18B$1.02B
7 Day Performance0.40%-4.30%-1.82%-1.05%
1 Month Performance1.62%-2.93%0.22%-1.40%
1 Year Performance-5.35%-13.09%17.25%13.93%

STERIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STE
STERIS
4.7488 of 5 stars
$220.43
-0.2%
$258.75
+17.4%
-3.7%$21.66B$5.14B46.8018,179Positive News
BDX
Becton, Dickinson and Company
4.9253 of 5 stars
$224.89
-0.1%
$278.29
+23.7%
-5.3%$65.22B$20.18B37.3674,000Positive News
EW
Edwards Lifesciences
4.4114 of 5 stars
$76.23
+0.3%
$79.95
+4.9%
-14.1%$44.96B$6.00B11.0019,800Positive News
IDXX
IDEXX Laboratories
4.5297 of 5 stars
$444.53
-3.3%
$533.75
+20.1%
-17.8%$36.40B$3.90B41.6611,000Positive News
DXCM
DexCom
4.7476 of 5 stars
$89.07
+5.9%
$99.06
+11.2%
-24.2%$34.79B$3.62B53.349,600Positive News
High Trading Volume
RMD
ResMed
4.3704 of 5 stars
$232.93
-2.7%
$244.73
+5.1%
+28.9%$34.21B$4.69B27.509,980Analyst Revision
Positive News
PODD
Insulet
4.3599 of 5 stars
$280.56
-0.6%
$277.13
-1.2%
+50.0%$19.68B$1.70B48.043,000Earnings Report
Analyst Forecast
News Coverage
Gap Down
BAX
Baxter International
4.1993 of 5 stars
$30.83
+0.7%
$39.44
+27.9%
-20.0%$15.74B$14.81B154.1660,000Earnings Report
Analyst Forecast
News Coverage
HOLX
Hologic
4.934 of 5 stars
$63.24
-0.6%
$85.77
+35.6%
-13.8%$14.27B$4.03B19.957,063
GMED
Globus Medical
4.8338 of 5 stars
$83.99
-0.2%
$96.91
+15.4%
+55.5%$11.44B$1.57B125.365,000Earnings Report
Analyst Forecast
News Coverage
MASI
Masimo
3.7241 of 5 stars
$181.31
+1.0%
$191.40
+5.6%
+34.8%$9.71B$2.05B125.045,200Analyst Revision
Positive News

Related Companies and Tools


This page (NYSE:STE) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners